190 related articles for article (PubMed ID: 20491777)
1. Novel therapeutic approach to eradicate tyrosine kinase inhibitor resistant chronic myeloid leukemia stem cells.
Naka K; Hoshii T; Hirao A
Cancer Sci; 2010 Jul; 101(7):1577-81. PubMed ID: 20491777
[TBL] [Abstract][Full Text] [Related]
2. Endoplasmic reticulum stress-mediated apoptosis in imatinib-resistant leukemic K562-r cells triggered by AMN107 combined with arsenic trioxide.
Xia Y; Fang H; Zhang J; Du Y
Exp Biol Med (Maywood); 2013 Aug; 238(8):932-42. PubMed ID: 23883479
[TBL] [Abstract][Full Text] [Related]
3. Microenvironmental protection of CML stem and progenitor cells from tyrosine kinase inhibitors through N-cadherin and Wnt-β-catenin signaling.
Zhang B; Li M; McDonald T; Holyoake TL; Moon RT; Campana D; Shultz L; Bhatia R
Blood; 2013 Mar; 121(10):1824-38. PubMed ID: 23299311
[TBL] [Abstract][Full Text] [Related]
4. β-Catenin is required for intrinsic but not extrinsic BCR-ABL1 kinase-independent resistance to tyrosine kinase inhibitors in chronic myeloid leukemia.
Eiring AM; Khorashad JS; Anderson DJ; Yu F; Redwine HM; Mason CC; Reynolds KR; Clair PM; Gantz KC; Zhang TY; Pomicter AD; Kraft IL; Bowler AD; Johnson K; Partlin MM; O'Hare T; Deininger MW
Leukemia; 2015 Dec; 29(12):2328-37. PubMed ID: 26202934
[TBL] [Abstract][Full Text] [Related]
5. BCL6-mediated repression of p53 is critical for leukemia stem cell survival in chronic myeloid leukemia.
Hurtz C; Hatzi K; Cerchietti L; Braig M; Park E; Kim YM; Herzog S; Ramezani-Rad P; Jumaa H; Müller MC; Hofmann WK; Hochhaus A; Ye BH; Agarwal A; Druker BJ; Shah NP; Melnick AM; Müschen M
J Exp Med; 2011 Oct; 208(11):2163-74. PubMed ID: 21911423
[TBL] [Abstract][Full Text] [Related]
6. Infliximab therapy together with tyrosine kinase inhibition targets leukemic stem cells in chronic myeloid leukemia.
Herrmann O; Kuepper MK; Bütow M; Costa IG; Appelmann I; Beier F; Luedde T; Braunschweig T; Koschmieder S; Brümmendorf TH; Schemionek M
BMC Cancer; 2019 Jul; 19(1):658. PubMed ID: 31272418
[TBL] [Abstract][Full Text] [Related]
7. CXCR2, a novel target to overcome tyrosine kinase inhibitor resistance in chronic myelogenous leukemia cells.
Kim JH; Lee SJ; Kang KW; Lee BH; Park Y; Kim BS
Biochem Pharmacol; 2021 Aug; 190():114658. PubMed ID: 34146540
[TBL] [Abstract][Full Text] [Related]
8. Novel HDAC inhibitor MAKV-8 and imatinib synergistically kill chronic myeloid leukemia cells via inhibition of BCR-ABL/MYC-signaling: effect on imatinib resistance and stem cells.
Lernoux M; Schnekenburger M; Losson H; Vermeulen K; Hahn H; Gérard D; Lee JY; Mazumder A; Ahamed M; Christov C; Kim DW; Dicato M; Bormans G; Han BW; Diederich M
Clin Epigenetics; 2020 May; 12(1):69. PubMed ID: 32430012
[TBL] [Abstract][Full Text] [Related]
9. Axl Blockade by BGB324 Inhibits BCR-ABL Tyrosine Kinase Inhibitor-Sensitive and -Resistant Chronic Myeloid Leukemia.
Ben-Batalla I; Erdmann R; Jørgensen H; Mitchell R; Ernst T; von Amsberg G; Schafhausen P; Velthaus JL; Rankin S; Clark RE; Koschmieder S; Schultze A; Mitra S; Vandenberghe P; Brümmendorf TH; Carmeliet P; Hochhaus A; Pantel K; Bokemeyer C; Helgason GV; Holyoake TL; Loges S
Clin Cancer Res; 2017 May; 23(9):2289-2300. PubMed ID: 27856601
[No Abstract] [Full Text] [Related]
10. Targeting Hedgehog signaling pathway and autophagy overcomes drug resistance of BCR-ABL-positive chronic myeloid leukemia.
Zeng X; Zhao H; Li Y; Fan J; Sun Y; Wang S; Wang Z; Song P; Ju D
Autophagy; 2015; 11(2):355-72. PubMed ID: 25701353
[TBL] [Abstract][Full Text] [Related]
11. Antimetabolic cooperativity with the clinically approved l-asparaginase and tyrosine kinase inhibitors to eradicate CML stem cells.
Trinh A; Khamari R; Fovez Q; Mahon FX; Turcq B; Bouscary D; Maboudou P; Joncquel M; Coiteux V; Germain N; Laine W; Dekiouk S; Jean-Pierre S; Maguer-Satta V; Ghesquiere B; Idziorek T; Quesnel B; Kluza J; Marchetti P
Mol Metab; 2022 Jan; 55():101410. PubMed ID: 34863941
[TBL] [Abstract][Full Text] [Related]
12. A novel HDAC inhibitor chidamide combined with imatinib synergistically targets tyrosine kinase inhibitor resistant chronic myeloid leukemia cells.
He B; Wang Q; Liu X; Lu Z; Han J; Pan C; Carter BZ; Liu Q; Xu N; Zhou H
Biomed Pharmacother; 2020 Sep; 129():110390. PubMed ID: 32563150
[TBL] [Abstract][Full Text] [Related]
13. Targeting BCR-ABL-Independent TKI Resistance in Chronic Myeloid Leukemia by mTOR and Autophagy Inhibition.
Mitchell R; Hopcroft LEM; Baquero P; Allan EK; Hewit K; James D; Hamilton G; Mukhopadhyay A; O'Prey J; Hair A; Melo JV; Chan E; Ryan KM; Maguer-Satta V; Druker BJ; Clark RE; Mitra S; Herzyk P; Nicolini FE; Salomoni P; Shanks E; Calabretta B; Holyoake TL; Helgason GV
J Natl Cancer Inst; 2018 May; 110(5):467-478. PubMed ID: 29165716
[TBL] [Abstract][Full Text] [Related]
14. Overcoming BCR::ABL1 dependent and independent survival mechanisms in chronic myeloid leukaemia using a multi-kinase targeting approach.
Busch C; Mulholland T; Zagnoni M; Dalby M; Berry C; Wheadon H
Cell Commun Signal; 2023 Nov; 21(1):342. PubMed ID: 38031192
[TBL] [Abstract][Full Text] [Related]
15. ADAM8 Is an Antigen of Tyrosine Kinase Inhibitor-Resistant Chronic Myeloid Leukemia Cells Identified by Patient-Derived Induced Pluripotent Stem Cells.
Miyauchi M; Koya J; Arai S; Yamazaki S; Honda A; Kataoka K; Yoshimi A; Taoka K; Kumano K; Kurokawa M
Stem Cell Reports; 2018 Mar; 10(3):1115-1130. PubMed ID: 29429960
[TBL] [Abstract][Full Text] [Related]
16. BCR-ABL kinase domain mutations, including 2 novel mutations in imatinib resistant Malaysian chronic myeloid leukemia patients-Frequency and clinical outcome.
Elias MH; Baba AA; Azlan H; Rosline H; Sim GA; Padmini M; Fadilah SA; Ankathil R
Leuk Res; 2014 Apr; 38(4):454-9. PubMed ID: 24456693
[TBL] [Abstract][Full Text] [Related]
17. System analysis of Huang-Lian-Jie-Du-Tang and their key active ingredients for overcoming CML resistance by suppression of leukemia stem cells.
Huang G; Yin Z; Wang X; Wen Z; Su R; Li C; Liu Y; Yang J; Hu H; Nie H; Zeng X; Fei J
Phytomedicine; 2023 Aug; 117():154918. PubMed ID: 37329755
[TBL] [Abstract][Full Text] [Related]
18. Effects of dasatinib on SRC kinase activity and downstream intracellular signaling in primitive chronic myelogenous leukemia hematopoietic cells.
Konig H; Copland M; Chu S; Jove R; Holyoake TL; Bhatia R
Cancer Res; 2008 Dec; 68(23):9624-33. PubMed ID: 19047139
[TBL] [Abstract][Full Text] [Related]
19. Mechanisms underlying therapeutic resistance of tyrosine kinase inhibitors in chronic myeloid leukemia.
Sun J; Hu R; Han M; Tan Y; Xie M; Gao S; Hu JF
Int J Biol Sci; 2024; 20(1):175-181. PubMed ID: 38164178
[TBL] [Abstract][Full Text] [Related]
20. Antitumor efficacy of arsenic/interferon in preclinical models of chronic myeloid leukemia resistant to tyrosine kinase inhibitors.
El Eit R; Itani AR; Nassar F; Rasbieh N; Jabbour M; Santina A; Zaatari G; Mahon FX; Bazarbachi A; Nasr R
Cancer; 2019 Aug; 125(16):2818-2828. PubMed ID: 31034603
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]